Evidence map›Paper›PMID 22819639›Full record

ArticleJournal of the American College of Surgeons2012

Heparin-binding epidermal growth factor-like growth factor and mesenchymal stem cells act synergistically to prevent experimental necrotizing enterocolitis.

Jixin Yang, Daniel Watkins, Chun-Liang Chen, Bharath Bhushan, Yu Zhou, Gail E Besner

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American College of Surgeons, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 3 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Human placental-derived stem cell therapy ameliorates experimental necrotizing enterocolitis.American journal of physiology. Gastrointestinal and liver physiology · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Jixin YangThe Research Institute at Nationwide Children's Hospital, Center for Perinatal Research, Department of Pediatric Surgery, Nationwide Children's Hospital, and the Ohio State University College of Medicine, Columbus, OH, USA.
Daniel Watkins
Chun-Liang Chen
Bharath Bhushan
Yu Zhou
Gail E Besner
Nationwide Children's Hospital · USTongji Hospital · CN

Funding

HB-EGF and Intestinal Ischemia/ReperfusionR01GM061193 · NIGMS · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI BESNER, GAIL E · 2002 to 2014
$3.6M
HB-EGF Therapy for Necrotizing EntercolitisR01DK074611 · NIDDK · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI BESNER, GAIL E · 2007 to 2011
$1.4M
NIDDK NIH HHS R01 DK074611NIGMS NIH HHS R01 GM061193
6 · The paper itself

Abstract

backgroundWe have shown that administration of heparin-binding EGF (epidermal growth factor)-like growth factor (HB-EGF) protects the intestines from experimental necrotizing enterocolitis (NEC). We have also demonstrated that systemically administered mesenchymal stem cells (MSC) can engraft into injured intestines. This study investigated the effects of HB-EGF on MSC in vitro, and whether MSC and HB-EGF can act synergistically to prevent NEC in vivo. STUDY

designIn vitro, the effect of HB-EGF on MSC proliferation, migration, and apoptosis was determined. In vivo, rat pups received MSC either intraperitoneally (IP) or intravenously (IV). Pups were assigned to 1 of 7 groups: Group 1, breast-fed; Group 2, experimental NEC; Group 3, NEC+HB-EGF; Group 4, NEC+MSC IP; Group 5, NEC+HB-EGF+MSC IP; Group 6, NEC+MSC IV; or Group 7, NEC+HB-EGF+MSC IV. Mesechymal stem cell engraftment, histologic injury, intestinal permeability, and mortality were determined.

resultsHeparin-binding EGF-like growth factor promoted MSC proliferation and migration, and decreased MSC apoptosis in vitro. In vivo, MSC administered IV had increased engraftment into NEC-injured intestine compared with MSC administered IP (p < 0.05). Heparin binding EGF-like growth factor increased engraftment of IP-administered MSC (p < 0.01) and IV-administered MSC (p < 0.05). Pups in Groups 3 to 7 had a decreased incidence of NEC compared with nontreated pups (Group 2), with the lowest incidence in pups treated with HB-EGF+MSC IV (p < 0.01). Pups in Group 7 had a significantly decreased incidence of intestinal dilation and perforation, and had the lowest intestinal permeability, compared with other treatment groups (p < 0.01). Pups in all experimental groups had significantly improved survival compared with pups exposed to NEC, with the best survival in Group 7 (p < 0.05).

conclusionsHeparin-binding EGF-like growth factor and MSC act synergistically to reduce injury and improve survival in experimental NEC.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsEnterocolitis, NecrotizingHeparin-binding EGF-like Growth FactorHumansIntercellular Signaling Peptides and ProteinsIn Vitro TechniquesMesenchymal Stem CellsRatsRats, Sprague-DawleyHBEGF protein, humanHbegf protein, ratHeparin-binding EGF-like Growth FactorIntercellular Signaling Peptides and Proteins

Identifiers

PMID22819639
PMCPMC3444529
OpenAlexW2053514844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.